David E Post

US Patent:

20110178500, Jul 21, 2011

Filed:

Dec 15, 2010

Appl. No.:

12/968744

Inventors:

Sherwin S. Shang - Vernon Hills IL, US
Esra Ozdaryal - Deerfield IL, US
David A. Post - Kenosha WI, US
Eduard N. Tsvirko - Arlington Heights IL, US

International Classification:

A61M 5/315
B23P 17/04

US Classification:

604506, 604228, 29428

Abstract:

Exemplary embodiments provide firing mechanism assemblies that minimize or eliminate a misfire of an automatic injection device that causes a delay in the delivery of an injection. Exemplary embodiments provide automatic injection devices including firing mechanism assemblies that minimize or eliminate a misfire that causes a delay in the delivery of an injection. Exemplary embodiments provide methods for minimizing or eliminating misfire that causes a delay in delivery of an injection in automatic injection devices. Exemplary embodiments provide methods for using automatic injection devices that are free of a misfire that causes delay in delivery of a therapeutic substance into a patient's body.

US Patent:

58010327, Sep 1, 1998

Filed:

Aug 1, 1996

Appl. No.:

8/691162

Inventors:

Diane L. Stassi - Highland Park IL
Gregory T. Maine - Gurnee IL
David A. Post - Kenosha WI
Mark T. Satter - Kenosha WI

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C12N 1500
C12N 114
C12N 1563

US Classification:

4351723

Abstract:

A process for producing high purity 6,12-dideoxyerythromycin A using recombinant DNA technology is disclosed. The erythromycin producing strain, Saccharopolyspora erythraea, lacking the erythromycin C-12 and C-6 hydroxylases produces a mixture of 6,12-dideoxyerythromycin A and the precursor molecule, 6-deoxyerythromycin D. To achieve conversion of the precursor to the final product, a second copy of eryG is inserted into a non-essential region of the Sac. erythraea chromosome resulting in high purity 6,12-dideoxyerythromycin A.

US Patent:

57861811, Jul 28, 1998

Filed:

Jan 28, 1997

Appl. No.:

8/789979

Inventors:

Diane L. Stassi - Highland Park IL
Gregory T. Maine - Gurnee IL
David A. Post - Kenosha WI
Mark T. Satter - Kenosha WI

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C12P 1962

US Classification:

435 76

Abstract:

A process for producing high purity 6,12-dideoxyerythromycin A using recombinant DNA technology is disclosed. The erythromycin producing strain, Saccharopolyspora erythraea, lacking the erythromycin C-12 and C-6 hydroxylases produces a mixture of 6,12-dideoxyerythromycin A and the precursor molecule, 6-deoxyerythromycin D. To achieve conversion of the precursor to the final product, a second copy of eryG is inserted into a non-essential region of the Sac. erythraea chromosome resulting in high purity 6,12-dideoxyerythromycin A.

US Patent:

20180272076, Sep 27, 2018

Filed:

Mar 5, 2018

Appl. No.:

15/912168

Inventors:

- North Chicago IL, US
Sherwin Shang - Vernon Hills IL, US
Esra Ozdaryal - Deerfield IL, US
Eduard Tsvirko - Arlington Heights IL, US
Edwin Chim - Vernon Hills IL, US
David Post - Kenosha WI, US
Vincent DiPalma - Hayward CA, US

International Classification:

A61M 5/32
A61M 5/20

Abstract:

Exemplary embodiments provide automatic injection devices in which a shroud is automatically deployed to protectively sheath a needle after an injection is performed. Exemplary embodiments also provide shroud deployment assemblies including a shroud and a syringe carrier that, when cooperatively configured in an automatic injection device, ensure that the shroud is automatically and completely deployed after an injection is performed using the automatic injection device. Exemplary embodiments are also configured to ensure that, once the shroud is deployed to an extended position to sheath the needle, accidental forces applied to the shroud do not succeed in subsequently retracting the shroud to a retracted position in which the needle would become exposed.

US Patent:

20180099094, Apr 12, 2018

Filed:

Oct 12, 2017

Appl. No.:

15/782751

Inventors:

- North Chicago IL, US
Esra Ozdaryal - Deerfield IL, US
Eduard N. Tsvirko - Arlington Heights IL, US
Edwin S. Chim - Vernon Hills IL, US
David A. Post - Kenosha WI, US
William P. Szechinski - Chicago IL, US
Shubha Chethan Somashekar - Waukegan IL, US
Ryan Brumund - Libertyville IL, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

A61M 5/20
A61M 5/32

Abstract:

Systems, methods, and devices are disclosed for facilitating injection of a medicament using an automatic injection device. The automatic injection device includes a housing defining a confined inner space and having a length extending from a proximal end to a distal end along a longitudinal axis. A helical biasing member, or spring, is disposed in the confined inner space, and the spring has an inner diameter at a middle portion that is greater than an inner diameter at the terminal ends of the spring. A syringe plunger has a second bifurcated end extending into an inner bore of the spring. The bifurcated end includes two flexible arms that are able to flex inwardly and outwardly relative to the longitudinal axis within the inner bore of the spring while maintaining an annular gap between the syringe plunger and the spring.

US Patent:

20140358117, Dec 4, 2014

Filed:

Apr 23, 2014

Appl. No.:

14/260093

Inventors:

- Hamilton, BM
Esra Ozdaryal - Deerfield IL, US
David A. Post - Vernon Hills IL, US
Eduard N. Tsvirko - Arlington Heights IL, US

International Classification:

A61M 5/20
A61M 5/31

US Classification:

604506, 604228

Abstract:

Exemplary embodiments provide firing mechanism assemblies that minimize or eliminate a misfire of an automatic injection device that causes a delay in the delivery of an injection. Exemplary embodiments provide automatic injection devices including firing mechanism assemblies that minimize or eliminate a misfire that causes a delay in the delivery of an injection. Exemplary embodiments provide methods for minimizing or eliminating misfire that causes a delay in delivery of an injection in automatic injection devices. Exemplary embodiments provide methods for using automatic injection devices that are free of a misfire that causes delay in delivery of a therapeutic substance into a patient's body.